Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer

Phase 2

Completed

• Conditions: Non Squamous Non Small Cell Lung Cancer
• Interventions: Drug: OGX-427; Drug: Placebo

• Registration Number: NCT01829113
• Lead Sponsor: SCRI Development Innovations, LLC

Brief Summary

This randomized phase II study will compare the efficacy and safety of the combination of carboplatin and pemetrexed with and without OGX-427 in patients with previously untreated advanced non-squamous NSCLC.

Detailed Description

Modern doublet chemotherapy improves survival in patients with advanced non-small cell lung cancer (NSCLC) compared with supportive care alone, with non-squamous NSCLC patients treated with platinum/pemetrexed living longer than patients treated with platinum/gemcitabine. Despite these advances, poor outcomes with advanced disease warrant exploration of novel drugs with unique mechanisms of action. Preclinical evidence in lung cancer models shows promising antitumor activity with OGX-427 in combination with platinum based therapy or pemetrexed. In this double-blind, placebo-controlled, Phase II study, pemetrexed and carboplatin plus OGX-427 followed by maintenance pemetrexed and OGX-427 will be compared with pemetrexed and carboplatin plus placebo followed by maintenance pemetrexed and placebo in patients with previously untreated advanced non-squamous NSCLC.

Study Timeline

• Study First Submitted: 2013-04-08
• Study First Submitted QC: 2013-04-10
• Study First Posted: 2013-04-11
• Study Start: 2013-07
• Primary Completion: 2017-04-19
• Study Completion: 2017-04-19
• Results First Submitted: 2018-04-18
• Status Verified: 2018-06
• Results First Submitted QC: 2018-06-06
• Last Update Submitted: 2018-06-06
• Results First Posted: 2018-06-08
• Last Update Posted: 2018-06-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 155

Inclusion Criteria

1. Histologic or cytologic diagnosis of advanced NSCLC, excluding squamous cell and small cell histology. Tumors with mixed NSCLC histologies are eligible, as long as the predominant histology is not squamous. If small-cell elements are present or not otherwise specified histologically, the patient is not eligible.

2. Metastatic disease (according to American Joint Committee on Cancer (AJCC) staging system, v7.0).

3. No prior systemic chemotherapy, immunotherapy, targeted therapy, or biological therapy for metastatic disease; previous adjuvant or neoadjuvant therapy for Stage I, II, or III disease is allowed as long as the interval from the end of treatment until disease progression was >12 months.

4. No prior radiation therapy to the whole pelvis or to ≥25% of the total bone marrow area. Other radiation therapy must be completed at least 2 weeks prior to study entry. Must have recovered from acute adverse effects prior to study entry.

5. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

6. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.

7. Baseline laboratory values as follows:

   • Absolute neutrophil count (ANC) ≥1500/μL
   • Hemoglobin (Hgb) ≥10 g/dL
   • Platelets ≥100,000/μL
   • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST), ≤3.0 x the upper limit of normal (ULN); 5 x ULN if known hepatic metastases.
   • Total bilirubin ≤1.5 x ULN, unless secondary to Gilbert's disease
   • Serum creatinine ≤1.5 x ULN. If creatinine is >1.5, calculate creatinine clearance (CrCl) ≥45 mL/min by the Cockcroft-Gault method:

   Glomerular Filtration Rate (GFR) = (140-age) x (weight/kg) x (0.85 if female)/(72 x serum creatinine mg/dL)

8. Fertile male patients willing to use adequate contraceptive measures.

9. Female patients who are not of child-bearing potential, and fertile female patients of child-bearing potential who agree to use adequate contraceptive measures, who are not breastfeeding, and who have a negative serum or urine pregnancy test within 72 hours prior to start of randomization.

10. Life expectancy ≥ 12 weeks.

11. Must be ≥18 years of age at the time of consent.

12. Willingness and ability to comply with trial and follow-up procedures.

13. Ability to understand the nature of this trial and give written informed consent.

Exclusion Criteria

1. Known anaplastic lymphoma kinase (ALK) translocation and epidermal growth factor receptor (EGFR) "activating" mutations where first-line treatment with targeted tyrosine kinase inhibitor therapy is more appropriate.

2. Known central nervous system (CNS) disease other than neurologically stable, treated brain metastases defined as metastasis having no evidence of progression or hemorrhage after treatment and no ongoing requirements for corticosteroids, (e.g., dexamethasone) for at least 2 weeks.

3. Any of the following cardiac diseases currently or within the last 6 months as defined by New York Heart Association (NYHA) ≥ Class 2:

   • Unstable angina pectoris
   • Congestive heart failure
   • Acute myocardial infarction
   • Conduction abnormality not controlled with pacemaker or medication
   • Significant ventricular or supraventricular arrhythmias (Patients with chronic rate-controlled atrial fibrillation in the absence of other cardiac abnormalities are eligible).

4. Patients currently receiving therapeutic anticoagulation.

5. Pregnant or lactating women.

6. Any serious, active underlying medical condition that would impair the ability of the patient to receive study treatment, such as diabetes mellitus or infection.

7. Unable or unwilling to take folic acid or vitamin B12.

8. Active second malignancy (except non-melanomatous skin or superficial bladder cancer) defined as requiring current need for cancer therapy or at high risk of recurrence (>30%) during the study.

9. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.

10. Inability or unwillingness to comply with trial and/or follow-up procedures outlined in the protocol.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
OGX-427	OGX-427	Three loading doses of OGX-427 at 600mg intravenously (IV) will be administered over 9 days. Following the loading dose period, OGX-427 will be administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle during the Treatment Phase. The Treatment Phase will be followed by a Maintenance Phase of OGX-427 administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle.
Placebo	Placebo	Three loading doses of placebo will be administered intravenously (IV) over 9 days. Following the loading dose period, placebo will be administered IV weekly Days 1, 8 and 15 of each 21 day cycle during the Treatment Phase. The Treatment Phase will be followed by a Maintenance Phase of placebo administered IV weekly Days 1, 8 and 15 of each 21 day cycle.

Primary Outcome Measures

Name	Time	Method
Median Progression-Free Survival	Every 6 weeks for up to 24 months	Defined as the time (in months) from date of randomization to the date of first observation of progression based on radiological assessment by Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1, or date of death from any cause, in the absence of progressive disease (PD) or censored at the date of last adequate tumor assessment. Progressive Disease is defined by RECIST v1.1 as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest (nadir) sum while on study (this includes the baseline sum if that is the smallest on study), or the appearance of one or more new lesions.

Secondary Outcome Measures

Name	Time	Method
Number of OGX-427 Versus Placebo Participants With an Objective Response	Every 6 weeks for up to 24 months	Defined as the number of patients with objective evidence of complete or partial response (CR or PR) using RECIST v 1.1. A CR is the complete disappearance of all target lesions. A PR is a decrease in baseline of 30% or more of the diameter(s) of all target lesions.
Median Overall Survival	Every 6 weeks for up to 41 months	Defined as the time (in months) from date of randomization to date of death from any cause, or censored at the date last known alive.
Number of Patients With a Treatment-Related Adverse Event as a Measure of Safety.	Weekly during each 21 days cycle and for 30 days after last dose for up to 29 Months	A treatment-related adverse event was any untoward medical occurrence in a participant which was considered to have a relationship with the study drug (suspected to be possibly or probably related to the study drug per the Investigator's assessment). Adverse events were evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03.

Trial Locations

Locations (16)

Tennessee Oncology; 🇺🇸 Nashville, Tennessee, United States

Florida Cancer Specialists-South; 🇺🇸 Fort Myers, Florida, United States

Oncology Hematology Care, Inc.; 🇺🇸 Cincinnati, Ohio, United States

South Carolina Oncology Associates; 🇺🇸 Columbia, South Carolina, United States

Florida Cancer Specialists-North; 🇺🇸 Saint Petersburg, Florida, United States

Tennessee Oncology - Chattanooga; 🇺🇸 Chattanooga, Tennessee, United States

Hematology-Oncology Associates of Northern NJ; 🇺🇸 Morristown, New Jersey, United States

The Center for Cancer and Blood Disorders; 🇺🇸 Fort Worth, Texas, United States

Rocky Mountain Cancer Center; 🇺🇸 Denver, Colorado, United States

Nebraska Methodist Hospital; 🇺🇸 Omaha, Nebraska, United States

Center for Cancer and Blood Disorders; 🇺🇸 Bethesda, Maryland, United States

Peninsula Cancer Institute; 🇺🇸 Newport News, Virginia, United States

Florida Hospital Cancer Insitute; 🇺🇸 Orlando, Florida, United States

Baptist Hospital East; 🇺🇸 Louisville, Kentucky, United States

Research Medical Center; 🇺🇸 Kansas City, Missouri, United States

Virginia Cancer Institute; 🇺🇸 Richmond, Virginia, United States